Better Genetic Tests for Antidepressant Selection

Improving genotyping for precision medicine
Better Genetic Tests for Antidepressant Selection
Project Status: In progress
Project administered by: SAHMRI

Exploring the genetics of antidepressant medications

The majority of antidepressant medications are processed in our body by a protein (enzyme) called CYP2D6. Some people might not have the gene that produces this protein, whilst most people have it, it can be non-functional or abnormal. This can change the way antidepressant medications are processed in our body and may mean they do not work or even cause adverse effects, causing prescribed medications to be ineffective.

Our research is intended to find out more about this protein (enzyme) and the gene that produces it with the hope of improving treatment and minimising side effects. We want to collect blood samples from individuals who are currently using or have used antidepressant medications in the past. Our research team will help to improve the way the critically important CYP2D6 gene is explored. We seek your assistance in providing a blood sample at our SAHMRI clinic, North Terrace, Adelaide. To be included in our research you will be able to attend an appointment at our SAHMRI clinic to provide a blood sample. You must be aged from 18 - 75 years old, but additionally you will have previously or currently used antidepressant medications. We will also ask you to complete a few brief online questionnaires. Your participation in this research will not be paid, but you will be contributing and supporting ongoing mental health research.

Contact Dr Martin Lewis at martin.lewis@sahmri.com if you are willing to assist us with this project.

This project is funded by the Breakthrough Mental Health Foundation